IL17A and triple-A syndrome: Sharma et al. found that treatment with human PL-MSCs (106 injected on day 1) on mice showed suppression of mononuclear cell proliferation and proinflammatory cytokine IL-17 production (which promotes vascular inflammation and atherosclerosis, with proven effects in AAA also in this study), attenuating AAA formation34.